Elevated level of von Willebrand factor as an additional risk factor for cardiovascular events in patients with early coronary atherosclerosis
https://doi.org/10.18705/2311-4495-2022-9-2-15-26
Abstract
Background. One of the urgent problem of modern cardiology is the search for markers to assess the risk of CV (cardiovascular) events in patients with CAD.
Objective. To evaluate the level of von Willebrand factor (vWF) in the blood plasma of patients with early onset of CAD and the study of the relationship between vWF hyperproduction and the risk of recurrent CV events.
Design and methods. We examined 80 patients who underwent acute myocardial infarction and/or surgical treatment of CAD in the amount of percutaneous coronary intervention or coronary artery bypass surgery at the age of up to 55 years (men) and up to 60 years (women).
Results. The following predictors of an unfavorable course of coronary artery disease in the examined patients were identified: an increased level of vWF, a higher BMI, and hypoalphacholesterolemia at the inclusion in the study. Among patients with normal vWF, no adverse CV events were recorded after 2 years of observation. A number of factors included in the prognostic model for the development of a recurrent CV event were identified: vWF level, age, BMI, hyperglycemia, and carotid atherosclerosis. Model demonstrated 92.5 % agreement between the forecast and the observation.
Conclusions. Elevated plasma vWF levels may serve as an additional risk factor for the development of recurrent CV events in patients with early manifestations of CAD.
About the Authors
I. V. Alekseeva
Center for cardiac medicine “Chernaya Rechka”
Russian Federation
Competing Interests:
Russian Federation
Irina V. Alekseeva, Head of the diagnostic center
Primorskoe highway, 648, pos. Molodezhnoye, Saint Petersburg, 197729
Competing Interests:
The authors declare no conflict of interest.
L. V. Vasina
Academician I. P. Pavlov First Saint Petersburg State Medical University
Russian Federation
Competing Interests:
Russian Federation
Lyubov V. Vasina, MD, Head of the Department of Biological Chemistry
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest.
E. V. Baranova
Center of atherosclerosis and lipid disorders, L. G. Sokolov Northwest District Scientific and Clinical Center
Russian Federation
Competing Interests:
Russian Federation
Elena V. Baranova, cardiologist
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest.
M. V. Muzalevskaya
Center of atherosclerosis and lipid disorders, L. G. Sokolov Northwest District Scientific and Clinical Center
Russian Federation
Competing Interests:
Russian Federation
Maria V. Muzalevskaya, cardiologist-consultant
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest.
S. G. Grigоriev
Federal state budgetary military educational institution of higher education “Military Medical Academy named after S. M. Kirov” of the Ministry of defence of the Russian Federation; Children’s Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency
Russian Federation
Competing Interests:
Russian Federation
Stepan G. Grigoriev, MD, professor, Senior Researcher at the Kirov Military Medical Academy, Senior Researcher, Children’s Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest.
S. A. Urazgildeeva
Center for cardiac medicine “Chernaya Rechka”; Center of atherosclerosis and lipid disorders, L. G. Sokolov Northwest District Scientific and Clinical Center; Scientific, Clinical and Educational Center “Cardiology”, Saint-Petersburg State University
Russian Federation
Competing Interests:
Russian Federation
Soreya A. Urazgildeeva, MD, leading researcher of the Department of Atherosclerosis, Scientific-Clinical and Educational Center “Cardiology”, Faculty of Medicine, Saint Petersburg State University; head of the Center for Clinical Lipidology, Center of Cardiac Medicine “Chernaya Rechka”; cardiologist consultant, Center for Atherosclerosis and Lipid Metabolism Disorders, L. G. Sokolov Northwest District Scientific and Clinical Center
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest.
References
1. Wu MD, Atkinson TM, Lindner JR. Platelets and von Willebrand factor in atherogenesis. Blood. 2017; 129(11):1415–1419. DOI: 10.1182/blood-2016-07-692673.
2. Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie. 2009; 29(1):32–38.
3. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006; 4(6):1186–1193.
4. Fitzgibbon GM, Burggraf GW, Groves TD et al. A double Master’s two-step test: clinical, angiographic and hemodynamic correlations. Ann Intern Med. 1971; 74(4):509–517. DOI: 10.7326/0003-4819-74-4-509.
5. Diagnostics and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations. 7 review. 2017; 1(38):7–34. In Russian.
6. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997; 96(4):1102–1108. DOI: 10.1161/01.cir.96.4.1102.
7. Wang X, Zhao J, Zhang Y, et al. Kinetics of plasma von Willebrand factor in acute myocardial infarction patients: a meta-analysis. Oncotarget. 2017; 8(52):90371–90379. DOI: 10.18632/oncotarget.20091.
8. Yan B, Wang Q, Du W, et al. Elevated Plasma von Willebrand Factor Antigen and Activity Levels Are Associated With the Severity of Coronary Stenosis. Clin Appl Thromb Hemost. 2020; 26:1076029619900552. DOI: 10.1177/1076029619900552.
9. Fuchs I, Frossard M, Spiel A, et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost. 2006; 4(12):2547–2552. DOI: 10.1111/j.1538-7836.2006.02239.x.
10. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000; 283(2):221–228. DOI: 10.1001/jama.283.2.221.
11. Kato Y, Iwata A, Futami M, et al. Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins. Medicine (Baltimore). 2018; 97(17):e0589. DOI: 10.1097/MD.0000000000010589.
12. Sahebkar A, Serban C, Ursoniu S, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016; 115(3):520–532. DOI: 10.1160/TH15-08-0620.
13. Zhang L, Su J, Shen F, et al. A novel monoclonal antibody against the von Willebrand Factor A2 domain reduces its cleavage by ADAMTS13. J Hematol Oncol. 2017; 10(1):42. DOI: 10.1186/s13045-017-0407-1.
14. Dellborg M, Bonaca MP, Storey RF, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019; 5(4):200–206. DOI: 10.1093/ehjcvp/pvz020.
15. Gradolí J, Vidal V, Brady AJ, et al. Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study. Eur Cardiol. 2018; 13(2):115–118. DOI: 10.15420/ecr.2018.12.2.
Review
For citations:
Alekseeva I.V., Vasina L.V., Baranova E.V., Muzalevskaya M.V., Grigоriev S.G., Urazgildeeva S.A. Elevated level of von Willebrand factor as an additional risk factor for cardiovascular events in patients with early coronary atherosclerosis. Translational Medicine. 2022;9(2):15-26. (In Russ.) https://doi.org/10.18705/2311-4495-2022-9-2-15-26
Views:
1283
Email this article 